Search Results - Jennifer Edelmann

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era? by Jennifer Edelmann, Jitka Malcikova, Jitka Malcikova, John C. Riches, John C. Riches

    Published in Frontiers in Oncology (2023-02-01)
    Get full text
    Article


  2. 2

    Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways by Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben

    Published in iScience (2021-02-01)
    Get full text
    Article


  3. 3

    Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations by Michael W.M. Kühn, Lars Bullinger, Stefan Gröschel, Jan Krönke, Jennifer Edelmann, Frank G. Rücker, Karina Eiwen, Peter Paschka, Verena I. Gaidzik, Karlheinz Holzmann, Richard F. Schlenk, Hartmut Döhner, Konstanze Döhner

    Published in Haematologica (2014-08-01)
    Get full text
    Article


  4. 4

    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription by Jennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, Emily A. Saunderson, Billy M. C. Jebaraj, Daniela Steinbrecher, Anna Dolnik, Tamara J. Blätte, Dan A. Landau, Jenny Saub, Sven Estenfelder, Stefan Ibach, Florence Cymbalista, Veronique Leblond, Alain Delmer, Jasmin Bahlo, Sandra Robrecht, Kirsten Fischer, Valentin Goede, Lars Bullinger, Catherine J. Wu, Daniel Mertens, Gabriella Ficz, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

    Published in Haematologica (2020-05-01)
    Get full text
    Article


Search Tools: